Fig. 1 · Structure

Documents & Downloads

Medroxyprogesterone Acetate

Cat. No. A11625 CAS 71-58-9

progesterone receptor agonist

Medroxyprogesterone acetate is a progestin, a synthetic variant of the human hormone progesterone and a potent progesterone receptor agonist.

In Stock

Publications for Medroxyprogesterone Acetate

2 publications citing this product

  1. Xijian Wang, .et al. , 3 Biotech, 2020, Sep;10(9):377 PMID: 32802719
  2. Xiucui Bao, .et al. , J Anal Methods Chem, 2019, Article ID 5676159 PMID: 31827972

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

Medroxyprogesterone acetate (MPA) activates progesterone receptor-dependent transcription in cell reporters, with activity depending on receptor isoform and cell background. In engineered AR-positive breast cells, it also regulates androgen-responsive endogenous genes; this overlap with DHT is incomplete. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
progestogen Receptor

Medroxyprogesterone Acetate Research Summary

This section summarizes 3 in vitro studies and 1 in vivo study of Medroxyprogesterone Acetate from 3 published references. In vitro models include authenticated, mycoplasma-negative human MCF-7 BUS breast cancer cells.

Medroxyprogesterone Acetate In Vitro Studies

In MCF-7 BUS breast cancer cells, MPA increased the MTT-based proliferation readout over 120 hours. The reported EC50 was 0.1 ± 0.03 pM (SEM), an assay-specific response rather than a receptor-binding measurement. The maximal response was not significantly different from estradiol, and 1 nM MPA did not significantly change the response to 1 nM estradiol. [2]

MPA activates progesterone receptor-dependent transcription

Cell-based study · T47Dco breast cancer cells; HeLa and T47D-Y derivatives expressing PR-A or PR-B [1]

MPA activated a PRE2/luciferase reporter. Relative activity versus R5020 depended on cell background and PR isoform; engineered T47D-Y cells showed lower MPA activity.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
PRE2/luciferase transcription normalized to Renilla and 1 µmol/l R5020Reporter activity MPA was active; approximately similar to R5020 in T47Dco except at 1000 nmol/l, with cell- and isoform-dependent differences.[1]

Literature-Reported Treatment Conditions

Treatment concentration
0.01–1000 nmol/l
Exposure duration
20 hours (Methods and Figure 2 caption)
Method
Cell treatment followed by luciferase/Renilla reporter measurement.
Vehicle
Ethanol
Methods and source locations

Compound reported in the paper: Medroxyprogesterone acetate; Compound label in the paper: MPA

Reported research material; no Adooq lot equivalence established.

Materials and methods: Transcription assays; Results: Synthetic progestins and progesterone receptor; Figure 2a–e

PRE2/luciferase transcription normalized to Renilla and 1 µmol/l R5020: Luciferase reporter; triplicate; mean ± standard error — Figure 2a–e and associated Results; Transcription assays

Androgen-responsive endogenous gene regulation by MPA

Cell-based study · PR-negative, engineered AR-positive Y-AR human breast cancer cells; parental T47D-Y controls [1]

MPA and DHT shared substantial gene regulation, including F3, MAF-B and KRT4 induction. The DHT-responsive p57 transcript was not similarly induced by MPA.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Endogenous androgen-responsive transcript regulationQualitative gene expression F3, MAF-B and KRT4 were induced by MPA and DHT; p57 was DHT-selective in the validation panel.[1]

Literature-Reported Treatment Conditions

Treatment concentration
MPA: 10 nmol/l or 1 µmol/l; DHT and progesterone comparators: 10 nmol/l
Exposure duration
6 hours
Method
Affymetrix expression profiling with selected transcript RT-PCR confirmation.
Vehicle
Ethanol
Methods and source locations

Compound reported in the paper: Medroxyprogesterone acetate; Compound label in the paper: MPA

Reported research material; no Adooq lot equivalence established.

Expression profiling and RT-PCR methods; Results: Expression profiling of medroxyprogesterone acetate versus dihydrotestosterone; Figure 7a–b; Y-AR validation in Figure 6

Endogenous androgen-responsive transcript regulation: Microarray selection: ≥2-fold, P<0.05; RT-PCR confirmation with GAPDH control — Figure 7a–b and associated Results; Expression profiling and RT-PCR methods

MPA increases MTT signal in MCF-7 BUS cells

Cell-based study · Authenticated, mycoplasma-negative human MCF-7 BUS breast cancer cells [2]

MPA increased MTT-based proliferation readout with a reported EC50 of 0.1 ± 0.03 pM (SEM). Its fitted maximal response was not significantly different from estradiol. Adding 1 nM MPA did not significantly change the estradiol response.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
MTT-based proliferation responseEC50 ± SEM 0.1 ± 0.03 pM[2]
Fitted maximal MTT response relative to estradiol maximum set to 100%Maximal response ± SEM 115 ± 11%[2]
MTT response with estradiol and MPAComparison No significant difference from estradiol alone for the combination (P>0.05).[2]

Literature-Reported Treatment Conditions

Treatment concentration
Concentration-response series; 1 nM MPA in the equimolar estradiol comparison
Exposure duration
120 hours total; treatment renewed after 72 hours
Method
MTT cell viability assay used as a proliferation readout.
Vehicle
Vehicle control; solvent not specified in the acquired article
Co-treatment
Separate comparison: 1 nM MPA with 1 nM estradiol
Reported limits
Full concentration series is plotted rather than enumerated in the methods. Exact independent experiment number for each panel is not supplied; general methods state at least three independent experiments.
Methods and source locations

Compound reported in the paper: Medroxyprogesterone acetate; Compound label in the paper: MPA

Reported research material; no Adooq lot equivalence established.

Methods 2.1, 2.2, 2.8; Results 3.1; Figure 1A–D and embedded table

MTT-based proliferation response: Non-linear regression; ≥3 independent experiments per general Methods 2.8 — Figure 1A embedded table; Methods 2.2 and 2.8

Fitted maximal MTT response relative to estradiol maximum set to 100%: Non-linear regression; Figure 1B shows no significant efficacy differences — Figure 1A embedded table and Figure 1B

MTT response with estradiol and MPA: Figure caption reports Dunnett comparison to estradiol alone — Figure 1D and caption

Medroxyprogesterone Acetate In Vivo Studies

In ovariectomized ApoE-deficient mice, 90-day MPA pellet treatment shortened time to stable carotid occlusion despite reducing aortic plaque burden by about 20%. MPA plus estradiol also shortened occlusion time, while plaque burden was unchanged versus placebo. These opposing endpoints limit a general interpretation of vascular benefit. [3]

Opposing vascular endpoints after chronic MPA treatment

Animal study · Ovariectomized female ApoE-deficient mice (Maeda strain), Western-type diet [3]

MPA shortened time to stable carotid occlusion while reducing aortic plaque burden by about 20%. The MPA–estradiol combination also shortened occlusion time but did not significantly change plaque burden.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Time to stable carotid occlusion after photochemical injuryDirection and significance Shorter with MPA and MPA + estradiol versus placebo; P<0.05.[3]
Oil-Red-O-positive area fraction of thoracic/abdominal aortaRelative plaque burden About 20% lower with MPA; P<0.05 versus placebo. No effect detected with MPA + estradiol.[3]

Conditions shared by the study groups

Route
Subcutaneous slow-release pellet
Frequency
Continuous nominal release
Treatment course
90 days
Vehicle
Pellet; matrix not specified
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
MPA alone
MPA 27.7 µg/day
Placebo pelletShorter occlusion time and lower plaque burden versus placebo.[3]
MPA + estradiol
MPA 27.7 µg/day plus 17β-estradiol 1.1 µg/day
Placebo pelletShorter occlusion time; plaque burden not significantly changed versus placebo.[3]
MPA alone
Model: Ovariectomized female ApoE-deficient mice (Maeda strain), Western-type diet
Reported limits: No estradiol-only group; plasma MPA exposure not established.
MPA + estradiol
Model: Ovariectomized female ApoE-deficient mice (Maeda strain), Western-type diet
Reported limits: No estradiol-only group; plasma MPA exposure not established.
Methods and source locations

Compound reported in the paper: Medroxyprogesterone acetate; Compound label in the paper: MPA

Mouse pellet-formulation results; no exposure equivalence to catalog powder or humans established.

Methods: Animals, Photochemical induction of thrombosis, Determination of aortic plaque burden, Statistical analysis; Results: Arterial thrombosis and Aortic plaque burden; Figures 1 and 3

Time to stable carotid occlusion after photochemical injury: Figure 1C; stable occlusion defined as zero flow for ≥10 minutes; mean ± SEM — Figure 1C and caption; Methods: Photochemical induction of thrombosis

Oil-Red-O-positive area fraction of thoracic/abdominal aorta: En face aortic staining/image analysis; n=18–21 per group; mean ± SEM — Results: Aortic plaque burden; Figure 3A–B and caption

MPA alone · Methods: Animals, Photochemical induction of thrombosis, Determination of aortic plaque burden, Statistical analysis; Results: Arterial thrombosis and Aortic plaque burden; Figures 1 and 3

MPA + estradiol · Methods: Animals, Photochemical induction of thrombosis, Determination of aortic plaque burden, Statistical analysis; Results: Arterial thrombosis and Aortic plaque burden; Figures 1 and 3

Specifications

Manufacturer Adooq Bioscience
Actions Agonist
CAS Number 71-58-9
Applications progesterone receptor agonist
Formula C24H34O4
Molecular Weight 386.52
Synonyms Medroxyprogesterone 17-acetate; MPA
SMILES
CC1CC2C(CCC3(C2CCC3(C(=O)C)OC(=O)C)C)C4(C1=CC(=O)CC4)C

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 11 mg/mL (28.45 mM)
Water Insoluble
Ethanol Warmed: 11 mg/mL (28.45 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
1 mg/mL
Vehicle
5% DMSO+30% PEG 300+5% Tween 80+ddH2O

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Medroxyprogesterone Acetate Research References

  1. [1] Ghatge RP, Jacobsen BM, Schittone SA, et al. The progestational and androgenic properties of medroxyprogesterone acetate: gene regulatory overlap with dihydrotestosterone in breast cancer cells. Breast cancer research : BCR (2005). PMID: 16457685 DOI: 10.1186/bcr1340 Source material
  2. [2] Perkins MS, Louw-du Toit R, Jackson H, et al. Upregulation of an estrogen receptor-regulated gene by first generation progestins requires both the progesterone receptor and estrogen receptor alpha. Frontiers in endocrinology (2022). PMID: 36187129 DOI: 10.3389/fendo.2022.959396 Source material
  3. [3] Freudenberger T, Oppermann M, Marzoll A, et al. Differential effects of medroxyprogesterone acetate on thrombosis and atherosclerosis in mice. British journal of pharmacology (2009). PMID: 20050187 DOI: 10.1111/j.1476-5381.2009.00470.x Source material

Publications

2 publications citing this product

  1. Xijian Wang, .et al. , 3 Biotech, 2020, Sep;10(9):377 PMID: 32802719
  2. Xiucui Bao, .et al. , J Anal Methods Chem, 2019, Article ID 5676159 PMID: 31827972

Added to your cart

View Cart Checkout
Loading...